OWL Oncology Research
Mary McManus is a seasoned professional in clinical research and trial management, currently serving as Managing Partner at OWL Oncology Research since January 2022. McManus has extensive experience from previous roles, including Clinical Trial Manager Consultant at Harpoon Therapeutics and Senior Clinical Consultant at Merck, where responsibilities involved transferring clinical assets post-acquisition. At IQVIA, McManus held several positions, culminating in Associate Clinical Project Management Director, overseeing multiple global oncology trials. Earlier career milestones include leading clinical studies at Quintiles and QLT Inc., managing trials in oncology and dermatology, while ensuring compliance with GCP and regulatory standards. McManus holds a Bachelor of Science in Pre-Medicine from Southern Illinois University Edwardsville.
This person is not in any teams
This person is not in any offices
OWL Oncology Research
OWL Oncology Research®, a Functional Service Provider (FSP), is a global network of hundreds of experienced clinical research experts specializing in oncology and rare disease trial monitoring, management, consulting and oversight. We deliver the highest quality clinical trial services to the pharmaceutical and biotechnology industries. Our commitment is to ensure that your clinical trials are conducted effectively and efficiently so that new and promising treatments become available to the millions of people battling these diseases. We are committed to facilitating the growing development needs of biotechnology companies in a world where increasingly, large conglomerated contract research organizations (CRO) are defining industry standards for clinical research. These CRO-defined "standards" are often excessive, or even at odds with current regulatory and international guidance, resulting in tangential focus, misleading project scopes, and unnecessary costs. It is our standard and privilege to ensure that new, promising oncology therapeutics are granted the attention, respect, and experienced teams that they deserve, without the cost or intimidation of a large CRO.